Clinical nurse specialist CNS · 2025
Collaboration and Decision-Support Tools to Mitigate Nirmatrelvir/Ritonavir Drug Interactions.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pike Marsha L, Fischer Erin N, Hirn Sarah L, Kriewall Nicole E, Kudrna Cory, Schmit Tammy L, Tulledge-Scheitel Sidna M, Zhao Yanjun
Аннотация
PURPOSE/OBJECTIVES: Nirmatrelvir/ritonavir (Paxlovid) is used to treat mild to moderate COVID-19 for patients at high risk for disease progression. However, its use presents challenges due to drug-to-drug interactions that affect its effectiveness and the safety of coadministered medications. In response, a nurse-initiated protocol and interprofessional prescribing guidance were developed at a large nonprofit academic medical center to expedite proactive treatment for at-risk, ambulatory patients with COVID-19. The guidance was based on a standardized risk score.
DESCRIPTION OF THE PROJECT: Decision-support tools were developed collaboratively with the pharmacy team and built into the electronic health record to provide just-in-time directives for prescribers. Patients who would otherwise have been excluded were prescribed nirmatrelvir/ritonavir using evidence-based, drug-to-drug interaction management strategies coupled with patient education and supported by the team infrastructure.
OUTCOME: Between November 1, 2020, and February 1, 2023, 3802 patients at high risk for disease progression who had a documented drug-to-drug interaction with nirmatrelvir/ritonavir were evaluated for treatment. Of these patients, 2351 (61.8%) were treated.
CONCLUSION: Our management strategies efficiently and safely provided treatment to more than 60% of patients at high risk of disease progression who would otherwise have been excluded from receiving this medication option due to drug-to-drug interactions with nirmatrelvir/ritonavir.
DESCRIPTION OF THE PROJECT: Decision-support tools were developed collaboratively with the pharmacy team and built into the electronic health record to provide just-in-time directives for prescribers. Patients who would otherwise have been excluded were prescribed nirmatrelvir/ritonavir using evidence-based, drug-to-drug interaction management strategies coupled with patient education and supported by the team infrastructure.
OUTCOME: Between November 1, 2020, and February 1, 2023, 3802 patients at high risk for disease progression who had a documented drug-to-drug interaction with nirmatrelvir/ritonavir were evaluated for treatment. Of these patients, 2351 (61.8%) were treated.
CONCLUSION: Our management strategies efficiently and safely provided treatment to more than 60% of patients at high risk of disease progression who would otherwise have been excluded from receiving this medication option due to drug-to-drug interactions with nirmatrelvir/ritonavir.